FGFR Inhibition in Urothelial Carcinoma

Although FGFR inhibitors are approved for advanced bladder cancer refractory to chemotherapy, they may provide a significant therapeutic benefit in patients with early-stage non–muscle-invasive bladder cancer. With an increasing understanding of the molecular underpinnings of FGFR-driven cancer form...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European urology 2024-09
Hauptverfasser:	Li, Roger, Linscott, Joshua, Catto, James W.F., Daneshmand, Siamak, Faltas, Bishoy M., Kamat, Ashish M., Meeks, Joshua J., Necchi, Andrea, Pradere, Benjamin, Ross, Jeffrey S., van der Heijden, Michiel S., van Rhijn, Bas W.G., Loriot, Yohann
Format:	Artikel
Sprache:	eng
Schlagworte:	FGFR inhibitor Immunotherapy Precision oncology Urothelial cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!